FCGR3A and myeloid sarcoma: Although data on soluble FCGR3A (sFCGR3A) in MS are sparse,—with one non-validated proteomic study in Chinese MS patients reporting decreased plasma levels of sFCGR3A in pwMS compared to HC (28)—the transmembrane form of FCGR3A is known to be highly expressed on nonclassical monocytes/macrophages (CD14+CD16++), CD16+CD56dim NK, and γδ T cells (29) as well as on microglia, oligodendrocyte precursor cells and immature oligodendrocytes (30).